July 3 (Reuters) - Summit Therapeutics ( SMMT ) and
AstraZeneca ( AZN ) are discussing a partnership deal worth as
much as $15 billion, Bloomberg News reported on Thursday, citing
people familiar with the matter.
Under the potential deal, AstraZeneca ( AZN ) could license Summit's
experimental lung-cancer treatment, ivonescimab, the report
said.
Summit did not immediately respond to Reuters request
seeking comment, while an AstraZeneca ( AZN ) spokesperson declined to
comment.
A deal between the companies could include an upfront
payment of several billion dollars to Summit and milestone
payments later on, Bloomberg News said.